Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK149203A
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK149203A is a candidate vaccine developed by GSK (GlaxoSmithKline) for the prevention of cytomegalovirus (CMV) infection. It is a recombinant glycoprotein B (gB) subunit vaccine, designed to elicit an immune response against CMV by targeting the viral gB protein, which plays a key role in viral entry into host cells. The vaccine has been evaluated in clinical trials as a prophylactic measure to prevent CMV infections, particularly in populations at risk such as transplant recipients and seronegative individuals[1][2]. Its mechanism of action involves inducing antibodies that neutralize CMV by binding to the gB antigen.
- Other names
- GSK Biologicals' recombinant CMV gB vaccineCytomegalovirus glycoprotein vaccine
02
Targets
gB (Human cytomegalovirus glycoprotein B)
Beyond the preview
Go deeper on GSK149203A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK149203A.